Kenvue (NYSE:KVUE – Free Report) had its target price hoisted by UBS Group from $19.00 to $20.00 in a research report released on Monday morning,Benzinga reports. They currently have a neutral rating on the stock.
Other equities research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. HSBC lowered their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Ten investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.29.
Kenvue Stock Performance
Shares of KVUE opened at $19.31 on Monday. The company has a market capitalization of $37.09 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The stock has a 50 day moving average of $18.41 and a 200 day moving average of $18.22. Kenvue has a 12 month low of $14.06 and a 12 month high of $20.13.
Kenvue (NYSE:KVUE – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, hitting analysts’ consensus estimates of $0.29. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.86 billion. During the same period in the previous year, the business posted $0.28 EPS. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Kenvue will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were given a dividend of $0.21 per share. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is currently 95.45%.
Institutional Trading of Kenvue
A number of hedge funds have recently made changes to their positions in KVUE. Johnson Financial Group Inc. purchased a new stake in Kenvue in the second quarter worth $26,000. CoreCap Advisors LLC lifted its position in shares of Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the last quarter. GK Wealth Management LLC bought a new stake in shares of Kenvue during the third quarter worth $27,000. Bell Investment Advisors Inc purchased a new stake in shares of Kenvue during the second quarter valued at $35,000. Finally, Keating Financial Advisory Services Inc. purchased a new stake in shares of Kenvue during the second quarter valued at $38,000. 97.64% of the stock is owned by institutional investors.
About Kenvue
Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.
The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.
Recommended Stories
- Five stocks we like better than Kenvue
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
